Adagene vs Apollomics
ADAG and APLM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADAG and APLM compare
Adagene scores higher on the StockData Score (5 against 0 for Apollomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADAG | APLM |
|---|---|---|
| Size and price | ||
| Share price | $1.71 | $17.68 |
| Change, 1 year | −3.4% | 7.0% |
| Change, 5 years | −82.5% | – |
| Beta (5Y) | 0.73 | 0.68 |
| Employees | 128 | 14 |
| StockData Score | ||
| Total score | 5 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 7333% | – |
| Revenue growth, 5Y average | 61.4% | – |
| Profitability | ||
| Operating margin | −279% | – |
| Net margin | −230% | – |
| FCF margin | −204% | – |
| Return on equity | −27.7% | – |
| Financial health | ||
| Debt / equity | 0.06 | – |
| Interest coverage | −46.3× | – |
| Current ratio | 5.02 (better) | 0.96 |
| Piotroski F-score | 4 | – |
| Ownership | ||
| Held by institutions | 32.5% | – |
| Held by insiders | 16.8% | 76.0% |
| Insider net buying, 12 months | $162K | $8.3M (better) |
Go deeper
- ADAG stock overview
- ADAG income statement
- ADAG valuation and score
- APLM stock overview
- APLM income statement
- APLM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.